Heidi Kunz's most recent trade in Phathom Pharmaceuticals Inc was a trade of 17,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 10,500 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Agilent Tech | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 121.18 per share. | 14 Mar 2025 | 1,819 | 58,851 (0%) | 0% | 121.2 | 220,426 | Common Stock |
| Phathom Pharmaceuticals Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 10,500 | 19,500 (0%) | 0% | 0 | Common Stock | |
| Agilent Tech | Heidi Kunz | Director | 15 Mar 2024 | 1,678 | 56,653 (0%) | 0% | 147.5 | 247,471 | Common Stock | |
| Agilent Tech | Heidi Kunz | Director | 05 Mar 2024 | 1,658 | 54,975 (0%) | 0% | 144.3 | 239,316 | Common Stock | |
| Icosavax Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 9,000 | 9,000 (0%) | 0% | 0 | Common Stock | |
| Agilent Tech | Heidi Kunz | Director | 16 Mar 2023 | 1,658 | 56,221 (0%) | 0% | 136.8 | 226,848 | Common Stock | |
| Agilent Tech | Heidi Kunz | Director | 23 Nov 2022 | 3,635 | 54,484 (0%) | 0% | 155.8 | 566,482 | Common Stock | |
| Icosavax Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 22,278 | 22,278 | - | - | Stock Option (Right to Buy)) | |
| Icosavax Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 5,543 | 14,293 | - | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Agilent Tech | Heidi Kunz | Director | 17 Mar 2022 | 1,785 | 57,849 (0%) | 0% | 136.8 | 244,224 | Common Stock | |
| Icosavax Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 15.00 per share. | 30 Jul 2021 | 8,750 | 8,750 | - | 15 | 131,250 | Common Stock |
| Phathom Pharmaceuticals Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Agilent Tech | Heidi Kunz | Director | 18 Mar 2021 | 1,850 | 55,767 (0%) | 0% | 121.6 | 224,947 | Common Stock | |
| Avanos Medical Inc | Heidi Kunz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 4,005 | 28,855 (0%) | 0% | 0 | Common Stock |